BiotechTube

talfirastide

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

DMD-Associated Dilated Cardiomyopathy

Conditions

DMD-Associated Dilated Cardiomyopathy

Trial Timeline

Aug 31, 2023 → Dec 1, 2024

NCT ID
NCT06013839

About talfirastide

talfirastide is a phase 2 stage product being developed by Constant Therapeutics for DMD-Associated Dilated Cardiomyopathy. The current trial status is unknown. This product is registered under clinical trial identifier NCT06013839. Target conditions include DMD-Associated Dilated Cardiomyopathy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06013839Phase 2UNKNOWN

Other Products from Constant Therapeutics

TXA127 + PlaceboPhase 2
44
Angiotensin 1-7Phase 2
44
TXA127 + PlaceboPhase 2
44
talfirastide + PlaceboPhase 2
44
TXA127 300 mcg/kg/day + TXA127 1000 mcg/kg/dayPhase 1
25